The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This protocol is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel) on the incidence of early and intermediate graft patency after CABG.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Prince Sultan Cardiac Center, Adult Cardiology Department.
• Treatments: Aspirin; Clopidogrel; Prasugrel Hydrochloride; Tirofiban

Criteria

Inclusion Criteria:

• All comer study where all patients undergoing coronary bypass surgery (CABG) will be randomized to one of the four treatment groups

Exclusion Criteria:

• Acute myocardial infarction (AMI) or cardiogenic shock

• Aortic dissection

• Mechanical valves.

• Contraindication to antiplatelets or aggrastat.

• Active bleeding or high risk of bleeding.

• History of hemorrhagic stroke any time.

• Recent history of embolic stroke or transient ischemic attack (TIA) less than 3 months.

• Active peptic ulcer disease (PUD).

• Liver derangement.

• Warfarin use.

• Heparin-induced thrombocytopenia (HIT) syndrome.

• Thrombocytopenia (platelet count <100,000/mm3), disorders of platelet function